Considering unhealthy eating patterns or may be genetic disorders, as per a report by EFFCA, more than 10 million people around the globe are suffering from inflammatory bowel disease or IBD. While there is no permanent cure for this disease, if not diagnosed at the right time, the patient can suffer from severe abdominal pain, fatigue, or even has his Gastrointestinal (GI) tract permanently damaged. Unfortunately, most IBD patients get mistreated because of prevalent generalized and primitive treatment methods, which hardly make any difference to a patient’s health.
An innovative biotechnology company, Prometheus Biosciences, with its ground-breaking approach, promises to help patients in their fight against chronic IBD diseases like Crohn’s disease and ulcerative colitis. In an effort to provide a more precise diagnosis and accurate testing for IBD, researchers at Prometheus Biosciences have spent more than two decades combining patient data with drug development insights, creating a novel precision therapy approach.
It all started more than twenty years ago when Dr. Stephan Targan, in a medical center near Los Angeles, discovered transmembrane protein TL1A by pairing longitudinal clinical information with IBD patient bio-samples. With this innovation, he created an IBD Biobank and laid the foundation of Precision IBD. Over the years, this IBD Biobank evolved with the biotech and industry expertise of the members. In 2016, under the guidance of Scott Glenn and Jim Laur, the company was renamed Prometheus Biosciences.
Having spent years developing, testing, and validating their research and recently launching their IPO in March 2021, ensuring data and cyber security naturally becomes a high priority for the company. The operations of its development and research team might be way ahead of time, but the HR and business operations of the company were not very efficient because of manual interventions. The company faced various challenges in implementing access regulations and giving satisfactory experience to its new hires while maintaining compliance requirements.
In order to protect its valuable research data, Prometheus Biosciences needed a solution that ensures only trusted employees had access to high-level data and its terminated staff did not walk away with critical information. With these challenges in mind, they reached out to RoboMQ.
RoboMQ, by implementing its flagship product Hire2Retire as a pre-packaged end–to-end integration product, helped Prometheus Biosciences safeguard its research and sensitive data collected over the years. Hire2Retire integrated the company’s HRIS ADP with Hybrid AD(Active Directory), creating a stringent role-based access control system that regulates resource allocation and eliminates security and compliance risks. Through end-to-end automation in employee lifecycle management and identity provisioning, Prometheus Biosciences could
Berks Homes, a premier home builder in Pennsylvania, faced many challenges while managing employee profiles across multiple counties and roles until they…Know More
ServiceMaster uses Hire2Retire to keep employee profiles consistent, updated, and accurate across nine brands in all 50 states and beyond…Know More
In 2019, Katerra upgraded its HRIS from ADP to Workday. RoboMQ helped Katerra achieve a seamless transition, minimizing the impact of the HR system…Know More